Living with lung cancer often means spending more time in waiting rooms than in the moments that matter. But that could ...
Lung cancer remains the leading cause of cancer death, but advances in screening, surgery and personalized treatment are ...
Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...
Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...
Traditionally, lung cancer is associated with older patients, specifically men who smoked. But doctors say that's beginning ...
Nuvalent said its drug for ALK+ lung cancer shrank tumors in more than a quarter of patients whose disease had returned after ...
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny ...
"In the middle of all the scans I thought... I'm fit and healthy... people like me don't get lung cancer, so to say it was a ...
Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.
This summer, 75-year-old Antioch Township Treasurer and Mesick resident Kathy Soerries was preparing for a family vacation to ...
When Sydney Barned was first diagnosed with stage 4 lung cancer, she was just 33 years old — a young medical intern focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback